TruScient
dibotermin alfa
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for TruScient has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 03/02/2015
Authorisation details
| Product details | |
|---|---|
| Name |
TruScient
|
| Agency product number |
EMEA/V/C/002000
|
| Active substance |
dibotermin alfa
|
| International non-proprietary name (INN) or common name |
dibotermin alfa
|
| Species |
Dogs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QM05BC01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Zoetis Belgium SA
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
14/12/2011
|
| Contact address |
Rue Laid Burniat 1 |
Product information
15/01/2015 TruScient - EMEA/V/C/002000 - IAIN/0005/G
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Pharmacotherapeutic group
Bone morphogenetic proteins
Therapeutic indication
Therapeutic indication
Osteoinductive agent for use in the treatment of long-bone fractures as an adjunct to standard surgical care using open fracture reduction in dogs.